John Campbell: Low dose Naltrexone

🟢
Peer-Reviewed Research
J
John Campbell

Video Summary · June 27, 2026

View Full Protocol →

Key Takeaways

  • Low Dose Naltrexone (LDN) (3-4.5mg daily) modulates opioid receptors and inhibits inflammatory pathways (TLR9/IL-6), showing promise for autoimmune diseases and cancer stabilization.
  • Start with 3mg LDN if under 70kg or 4.5mg LDN if over 70kg, but never exceed 4.5mg due to dose-dependent effects.
  • Taper up from 1.5mg over 1-2 weeks to minimize initial sleep disturbances or vivid dreams (common but temporary side effects).
  • LDN works via the levo form of naltrexone; higher doses (>4.5mg) become ineffective as the dextro form dominates.
  • For chronic conditions (MS, Crohn’s, arthritis), LDN may provide stabilization where conventional treatments fail.

Supplements & Protocols Mentioned

  • Low Dose Naltrexone (LDN): 3mg (≤70kg) or 4.5mg (>70kg) taken orally at bedtime. Start lower (1.5mg) and titrate up over 1-2 weeks.

Notable Quotes

“The trick is to pay a pharmacist to actually make it low enough dose… never go over 4.5mg.”

“Less is more… these drugs work far better at low doses than high doses.”

Bottom Line

Consider Low Dose Naltrexone (3-4.5mg nightly) for autoimmune or inflammatory conditions, starting low to assess tolerance. Work with a compounding pharmacist for accurate dosing.

Explore supplements mentioned in this video

Shop on iHerb →

Explore More

Watch the Full Video

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice. The research summaries presented here are based on published studies and should not be used as a substitute for professional medical consultation. Always consult a qualified healthcare provider before making any changes to your health regimen.

⚡ Research Insider Weekly

Peer-reviewed health research, simplified. Early access findings, clinical trial alerts & regulatory news — delivered weekly.

No spam. Unsubscribe anytime. Powered by Beehiiv.

From Our Research Network

Part of the Evidence-Based Research Network

Similar Posts